ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) had its price target lowered by equities researchers at Oppenheimer from $23.00 to $21.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a "market perform" rating on the biopharmaceutical company's stock. Oppenheimer's price objective suggests a potential upside of 14.63% from the company's current price.
Several other equities research analysts have also recently commented on ACAD. Citigroup reissued a "buy" rating and set a $33.00 price target (down from $40.00) on shares of ACADIA Pharmaceuticals in a research report on Friday, September 25th. Deutsche Bank reduced their price objective on shares of ACADIA Pharmaceuticals from $38.00 to $31.00 and set a "buy" rating for the company in a research note on Friday, September 25th. Weiss Ratings restated a "hold (c+)" rating on shares of ACADIA Pharmaceuticals in a report on Tuesday, November 10th. Bank of America reaffirmed a "buy" rating and issued a $14.50 target price on shares of ACADIA Pharmaceuticals in a research report on Wednesday, July 29th. Finally, Citizens Jmp lowered their target price on ACADIA Pharmaceuticals from $36.00 to $33.00 and set a "market outperform" rating on the stock in a research report on Friday, September 25th. Thirteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, ACADIA Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $31.13.
Read Our Latest Analysis on ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Stock Down 1.9%
Shares of ACAD stock opened at $18.32 on Wednesday. The company's fifty day simple moving average is $21.41 and its 200-day simple moving average is $23.30. The firm has a market cap of $3.17 billion, a PE ratio of 8.68 and a beta of 0.87. ACADIA Pharmaceuticals has a 12 month low of $15.85 and a 12 month high of $30.96.
ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last announced its earnings results on Wednesday, November 4th. The biopharmaceutical company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.20 by $0.11. The business had revenue of $342.30 million during the quarter, compared to analysts' expectations of $332.58 million. ACADIA Pharmaceuticals had a net margin of 30.13% and a return on equity of 8.90%. The firm's revenue was up 22.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.42 earnings per share. On average, equities analysts predict that ACADIA Pharmaceuticals will post 0.76 earnings per share for the current fiscal year.
Insider Activity at ACADIA Pharmaceuticals
In other news, EVP Mark Schneyer sold 3,321 shares of the business's stock in a transaction dated Friday, October 30th. The shares were sold at an average price of $20.88, for a total transaction of $69,342.48. Following the transaction, the executive vice president directly owned 71,322 shares in the company, valued at $1,489,203.36. The trade was a 4.45% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 26.20% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On ACADIA Pharmaceuticals
Several hedge funds have recently bought and sold shares of the company. Algert Global LLC bought a new stake in ACADIA Pharmaceuticals in the 3rd quarter valued at $2,073,000. Virtu Financial LLC bought a new position in ACADIA Pharmaceuticals during the 3rd quarter worth $296,000. Krensavage Asset Management LLC bought a new position in ACADIA Pharmaceuticals during the 3rd quarter worth $806,000. Goldman Sachs Group Inc. increased its position in ACADIA Pharmaceuticals by 79.1% during the 3rd quarter. Goldman Sachs Group Inc. now owns 4,621,932 shares of the biopharmaceutical company's stock worth $93,132,000 after buying an additional 2,041,817 shares during the period. Finally, Cetera Investment Advisers increased its position in ACADIA Pharmaceuticals by 9.1% during the 3rd quarter. Cetera Investment Advisers now owns 26,146 shares of the biopharmaceutical company's stock worth $527,000 after buying an additional 2,188 shares during the period. 96.71% of the stock is currently owned by institutional investors and hedge funds.
ACADIA Pharmaceuticals Company Profile
(
Get Free Report)
ACADIA Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for neurological and rare diseases. Founded in 1993 and headquartered in San Diego, California, the company conducts research and development alongside its commercial operations. Its marketed products include NUPLAZID (pimavanserin), approved in the United States to treat hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE (trofinetide), a treatment for Rett syndrome.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ACADIA Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ACADIA Pharmaceuticals wasn't on the list.
While ACADIA Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.